UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Financials Universal Vision Biotechnology Co., Ltd.
Equities
3218
TW0003218004
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 240 TWD | -0.21% |
|
-2.64% | -13.36% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,138 | 18,193 | 21,543 | 23,859 | 23,469 | 20,334 | - | - |
| Enterprise Value (EV) 1 | 4,542 | 17,754 | 21,019 | 22,590 | 23,469 | 18,211 | 17,785 | 16,449 |
| P/E ratio | - | 37.6 x | 36.2 x | 28.1 x | 22.4 x | 17.6 x | - | - |
| Yield | 2.96% | 1.76% | 1.77% | - | - | 3.52% | 4.21% | 4.53% |
| Capitalization / Revenue | 3.62 x | 8.86 x | 8.19 x | 6.83 x | 5.75 x | 4.49 x | 3.84 x | 3.18 x |
| EV / Revenue | 3.2 x | 8.65 x | 7.99 x | 6.47 x | 5.75 x | 4.02 x | 3.36 x | 2.57 x |
| EV / EBITDA | 9.23 x | 20.6 x | 19.3 x | 15.5 x | 13.3 x | 9.23 x | 7.72 x | 5.82 x |
| EV / FCF | - | 33.4 x | 35.8 x | 28.5 x | - | 11.4 x | 11.8 x | - |
| FCF Yield | - | 3% | 2.79% | 3.51% | - | 8.76% | 8.45% | - |
| Price to Book | 3.23 x | 9.51 x | 9.84 x | 8.96 x | - | 5.43 x | 4.6 x | 3.87 x |
| Nbr of stocks (in thousands) | 84,725 | 84,725 | 84,725 | 84,725 | 84,725 | 84,725 | - | - |
| Reference price 2 | 60.65 | 214.7 | 254.3 | 281.6 | 277.0 | 240.0 | 240.0 | 240.0 |
| Announcement Date | 3/22/20 | 3/23/21 | 3/30/22 | 3/28/23 | 3/14/24 | - | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,419 | 2,053 | 2,632 | 3,494 | 4,082 | 4,531 | 5,296 | 6,390 |
| EBITDA 1 | 492.1 | 860.5 | 1,088 | 1,453 | 1,758 | 1,972 | 2,303 | 2,828 |
| EBIT 1 | 247 | 596.5 | 768.5 | 1,081 | 1,312 | 1,458 | 1,722 | 2,115 |
| Operating Margin | 17.41% | 29.05% | 29.2% | 30.94% | 32.14% | 32.17% | 32.52% | 33.1% |
| Earnings before Tax (EBT) 1 | - | 602.1 | 763.1 | 1,092 | - | 1,453 | - | - |
| Net income 1 | - | 483.2 | 595.4 | 850.4 | - | 1,154 | - | - |
| Net margin | - | 23.54% | 22.62% | 24.34% | - | 25.47% | - | - |
| EPS 2 | - | 5.705 | 7.017 | 10.02 | 12.34 | 13.62 | - | - |
| Free Cash Flow 1 | - | 531.9 | 587.3 | 792.2 | - | 1,596 | 1,503 | - |
| FCF margin | - | 25.91% | 22.32% | 22.67% | - | 35.22% | 28.38% | - |
| FCF Conversion (EBITDA) | - | 61.82% | 53.98% | 54.51% | - | 80.92% | 65.27% | - |
| FCF Conversion (Net income) | - | 110.08% | 98.64% | 93.15% | - | 138.3% | - | - |
| Dividend per Share 2 | 1.797 | 3.774 | 4.492 | - | - | 8.440 | 10.10 | 10.86 |
| Announcement Date | 3/22/20 | 3/23/21 | 3/30/22 | 3/28/23 | 3/14/24 | - | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 669.7 | 737 | 835.6 | 789.3 | 911.4 | 957.7 | 1,028 | 999.4 | 1,062 | 992.9 | 1,078 | 1,058 | 1,177 | 1,132 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | 436 | 441.8 | 477 | 449.3 | - |
| EBIT 1 | 178.5 | 232 | 274.7 | 233 | 266.9 | 306.6 | 344.3 | 319.2 | 330.2 | 318.1 | 337.5 | 335 | 396 | 378 |
| Operating Margin | 26.65% | 31.47% | 32.88% | 29.52% | 29.28% | 32.01% | 33.48% | 31.94% | 31.11% | 32.04% | 31.31% | 31.65% | 33.64% | 33.38% |
| Earnings before Tax (EBT) 1 | 177.2 | 229.6 | 275.2 | 238.9 | 273.6 | 304.4 | 341.1 | 324.3 | 334.6 | - | 339 | 337 | 398 | 380 |
| Net income 1 | 134.4 | 184.1 | 213.3 | 187 | 206.4 | 243.6 | 266 | 259.8 | 266.2 | - | 269 | 266 | 315 | 303.5 |
| Net margin | 20.07% | 24.98% | 25.53% | 23.7% | 22.64% | 25.44% | 25.87% | 25.99% | 25.08% | - | 24.95% | 25.13% | 26.76% | 26.8% |
| EPS 2 | 1.581 | 2.165 | 2.516 | 2.210 | 2.434 | - | - | 3.066 | 3.140 | - | 3.175 | 3.140 | 3.720 | 3.585 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/30/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/14/24 | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 596 | 439 | 524 | 1,269 | - | 2,123 | 2,549 | 3,885 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 532 | 587 | 792 | - | 1,596 | 1,503 | - |
| ROE (net income / shareholders' equity) | 15.5% | 27.6% | 29% | 35.1% | - | 32.4% | 32.4% | 35.8% |
| ROA (Net income/ Total Assets) | 10% | 16.6% | 17.2% | 20.6% | - | 19.2% | 24.2% | - |
| Assets 1 | - | 2,908 | 3,459 | 4,120 | - | 6,010 | - | - |
| Book Value Per Share 2 | 18.80 | 22.60 | 25.80 | 31.40 | - | 44.20 | 52.10 | 62.10 |
| Cash Flow per Share | 5.690 | - | - | - | - | - | - | - |
| Capex 1 | - | 295 | 324 | 476 | - | 500 | 579 | - |
| Capex / Sales | - | 14.38% | 12.33% | 13.62% | - | 11.03% | 10.93% | - |
| Announcement Date | 3/22/20 | 3/23/21 | 3/30/22 | 3/28/23 | 3/14/24 | - | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
240
TWD
Average target price
313.8
TWD
Spread / Average Target
+30.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.36% | 623M | |
| +11.95% | 98.12B | |
| -6.10% | 17.66B | |
| -20.02% | 2.24B | |
| -8.37% | 1.54B | |
| +29.63% | 1.23B | |
| -35.36% | 735M | |
| -35.62% | 747M | |
| +24.04% | 494M | |
| +17.74% | 493M |
- Stock Market
- Equities
- 3218 Stock
- Financials Universal Vision Biotechnology Co., Ltd.
